surmount 2 tirzepatide Efficacy and safety of once‐weekly in Japanese participants with type diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT‐2 trial - Yamauchi - 2025 Clinical trials of subcutaneous tirzepatide

Serious risks reported with GLP-1 therapy include pancreatitis, gallbladder problems, low blood sugar (particularly alongside other diabetes medicines), kidney issues from dehydration, and allergic reactions

Many patients report benefits that extend beyond the scale, including: Improved confidence Better mobility Increased energy Reduced cravings Improved relationship with food Greater motivation to exercise Enhanced quality of life These changes often become just as meaningful as the weight loss itself

CA$ 37.40 You save CA$ 1.96

These differences aren't inherently problematic - pharmacists have extensive training in formulation science - but they do mean that a compounded product isn't identical to a brand-name product